English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background and aims: Essential hypertension and type 2 diabetes mellitus possess some common pathogenetic components, in particular, activation of immune inflammatory response, the intercellular mediators of which are cytokines. In our study, hypertensive patients were examined, depending on presence of concomitant prediabetes or type 2 diabetes mellitus, for the level of pro-inflammatory cytokines oncostatin M, interleukin-6 in conjunction with glucometabolic parameters and lipid metabolism parameters. Material and methods: A total of 94 hypertensive patients were examined. Oncostatin M and Interleukin-6 plasma level detected using ELISA (BSM). Results and conclusions: The 1st group consisted of hypertensive patients. The 2nd group included hypertensive patients with prediabetes. The 3rd group were hypertensive patients with type 2 diabetes mellitus. We have revealed the increased circulating level of oncostatin M and interleukin-6 in patients 1st group, which confirms the pathogenetic value of hypertension as a stimulus for hyperproduction of these cytokines. In 2nd group the level of oncostatin M and interleukin-6 decreased, which could probably be explained, on the one hand, by dual effects of the family of interleukin-6 the representatives of which either contribute to the development of insulin resistance or, vice versa, enhance the insulin sensitivity of tissues.

Oncostatin M, Interleukin-6, Glucometabolic Parameters and Lipid Profile in Hypertensive Patients with Prediabetes and Type 2 Diabetes Mellitus